Pfizer (PFE) Scores Phase 3 Cancer Win As FDA Broadens Another Oncology Approval

Pfizer (NYSE:PFE) reported positive Phase 3 MagnetisMM-32 results for ELREXFIO in relapsed or refractory multiple myeloma. The MagnetisMM-32 trial met its primary endpoint, showing a statistically significant and clinically meaningful progression free survival benefit versus standard regimens. The FDA expanded approval of TALZENNA plus XTANDI to earlier line use in metastatic prostate cancer with HRR gene mutations, based on Phase 3 data. Pfizer plans global regulatory submissions for...